Overview

The Gene Technology Act 2004 was enacted to regulate the handling, storage, use, and release of genetically modified organisms in Australia, with the aim of protecting human health and the environment from any potential risks. This legislation was introduced by the Australian Parliament to address the need for a comprehensive framework to manage the risks associated with genetic modification technologies. The Act's policy objective is to ensure that any potential risks are identified and managed effectively, while also promoting innovation and the safe use of biotechnology. The Office of the Gene Technology Regulator is responsible for assessing applications such as the proposed commercial supply of the genetically modified dengue vaccine, Qdenga, ensuring that all associated risks are thoroughly evaluated and managed before approval is granted for its use.

Scope and Application

The Gene Technology Act 2000, as amended by the legislation C2023G00998, applies to entities and individuals involved in the handling, research, and commercial supply of genetically modified organisms in Australia. Specifically, this act governs the activities of Takeda Pharmaceuticals Australia Pty Ltd in relation to the proposed commercial supply of the genetically modified dengue vaccine, Qdenga. The Act ensures that any genetically modified product intended for commercial use undergoes a rigorous assessment of potential risks to human health and the environment, as well as an evaluation of appropriate risk management measures. The Regulator's RARMP for this application is central to determining whether the licence for commercial supply should be granted. The geographic scope of this Act is national, with the Regulator operating under the Commonwealth jurisdiction, ensuring compliance across all states and territories. Notably, the Act does not specify exclusions, but certain activities may be exempt based on risk classifications and other regulatory provisions. The application process may also be influenced by subordinate instruments that provide additional guidelines or criteria for assessing GM products.

Key Provisions

The main operative sections of the legislation, C2023G00998, pertain to the assessment and potential licensing of the commercial supply of a genetically modified (GM) dengue vaccine, Qdenga. This includes the preparation of a Risk Assessment and Risk Management Plan (RARMP) (Section 1). The legislation also mandates that the vaccine must be registered by the Therapeutic Goods Administration (TGA) before it can be supplied commercially (Section 2). Section 3 provides for public consultation, inviting written submissions from interested parties before the Regulator makes a decision on the licence. The obligations imposed by the legislation include the preparation and submission of a RARMP by Takeda Pharmaceuticals Australia Pty Ltd (Section 4). This plan must detail the potential risks associated with the GM dengue vaccine and how they will be managed. Additionally, Section 5 outlines the requirement for the vaccine to be registered by the TGA, ensuring its quality, safety, and efficacy meet the necessary standards for human use. The legislation also places an obligation on the Regulator to consider any written submissions received during the consultation period before making a decision (Section 6). Section 7 of the legislation specifies that breaches of the regulatory requirements can result in various consequences. While the specific offences and penalties are not detailed in the text, it is implied that non-compliance with the assessment and registration requirements could lead to legal action. The potential civil and criminal consequences for such breaches could include fines, imprisonment, or other sanctions as prescribed by the relevant legislation governing the GM products and therapeutic goods. The maximum penalties would be determined by the courts based on the severity and nature of the breach.